Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Efficacy and Safety of Subcutaneous Self-administered Gefurulimab in Generalized Myasthenia Gravis: Primary Results From the Phase Three, Randomized, Double-blind, Placebo-controlled PREVAIL Study